UCARTCS1A is a SLAMF7 targeted allogeneic (donor-derived) CAR T-cell therapy being developed for multiple myeloma patients.

May 5, 2023: Cellectis has given up on its multiple myeloma CAR-T candidate UCARTCS1. With the phase 1 clinical trial two years behind schedule, and heavy investment needed to accelerate enrollment, the off-the-shelf cell therapy specialist is stopping the study and focusing its resources on three other candidates. Learn more

SparkCures ID 338
Developed By Cellectis S.A.
Generic Name UCARTCS1A
Treatment Classifications
Treatment Targets

Clinical Trials